Calendario›REGN›REGN10597 · BrILliance

REGN10597 · BrILliance

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

Ensayo de REGENERON PHARMACEUTICALS, INC. en Melanoma · Clear-Cell Renal-Cell Carcinoma (ccRCC) · Advanced Solid Tumors (del registro, en inglés).

Más ensayos de: Melanoma · Tumor sólido avanzado.

Fase

Fase 1/2

Estado

Reclutando pacientes

Participantes

240

previstos

Centros

11

Fin del objetivo primario

feb 2030

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en sep 2024.

Qué mide

Incidence of Dose-Limiting Toxicities (DLTs) (del registro, en inglés) (hasta el dia 29)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and effective the study drug(s) are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug(s) * How much study drug(s) is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06413680), actualizada en abr 2026.